Exscientia initiated with a Buy at TD Cowen

TD Cowen initiated coverage of Exscientia with a Buy rating and no price target. The company’s novel artificial intelligence platform and pipeline of next-generation oncology assets address specific shortcomings of first-generation drugs, the analyst tells investors in a research note. The firm believes Exscientia is well positioned to capitalize on years of clinical and preclinical data while paving the way for a new generation of AI-driven biotech companies.